Study aims to create the most robust, multi-omic dataset for patients with NSCLC Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset...
Tempus, a leader in artificial intelligence and precision medicine, today announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc. (Actuate), a clinical-stage biopharmaceutical company, to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests wi...
Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is cur...
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes in Chicago from June 3-7, 2022. Tempus is presenting fourteen abstracts, including one oral presentation, two poster discussions, and eleven poster presentations. “The re...
Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology. Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will he...
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline...
Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen). The expanded scope is anchored in new AI-based work, in which Tempus will collaborate with a multidisciplinary team of data scientists at Janssen to enhance the discov...
Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memor...
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics...
Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each...
